Literature DB >> 16006012

Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.

María Nieto1, Francisco J Gil-Bea, Esther Dalfó, Mar Cuadrado, Felipe Cabodevilla, Belén Sánchez, Silvia Catena, Teresa Sesma, Elena Ribé, Isidro Ferrer, María J Ramírez, Teresa Gómez-Isla.   

Abstract

In addition to genetic factors, environmental factors have long been suspected to contribute to the pathogenesis of Parkinson's disease (PD). We investigated the possible interaction between genetic factors and neurotoxins by testing whether alpha-synuclein A30P Tg5093 transgenic mice show increased sensitivity to secondary toxic insults like 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or rotenone. While sensitivity to chronic treatment with rotenone was not enhanced in the Tg5093 line, chronic treatment with 80 or 150 mg/kg MPTP resulted in increased deterioration of the nigrostriatal dopaminergic system as assessed by quantitation of nigral tyrosine hydroxylase (TH) positive neurons and striatal dopamine (DA) levels in Tg5093 mice when compared to non-transgenic littermate controls. Thus, the results of this study demonstrate a role for the overexpression of mutant human alpha-synuclein A30P in increased vulnerability of DA neurons to MPTP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006012     DOI: 10.1016/j.neurobiolaging.2005.04.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  41 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

3.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

Review 4.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 5.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

6.  Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

Authors:  Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2010-04-13       Impact factor: 14.195

7.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

Review 8.  Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Authors:  Xiaoyun Xu; Jinsha Huang; Jie Li; Ling Liu; Chao Han; Yan Shen; Guoxin Zhang; Haiyang Jiang; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Cell Prolif       Date:  2016-01-08       Impact factor: 6.831

Review 9.  Animal models of Parkinson's disease: vertebrate genetics.

Authors:  Yunjong Lee; Valina L Dawson; Ted M Dawson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.